Intensity Therapeutics, Inc.
INTS
$1.85
-$0.01-0.54%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.09M | 6.40M | 6.12M | 4.98M | 3.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.59M | 16.73M | 15.66M | 11.81M | 8.32M |
| Operating Income | -16.59M | -16.73M | -15.66M | -11.81M | -8.32M |
| Income Before Tax | -16.27M | -16.26M | -15.08M | -13.81M | -10.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.27 | -16.26 | -15.08 | -13.81 | -10.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.27M | -16.26M | -15.08M | -13.81M | -10.54M |
| EBIT | -16.59M | -16.73M | -15.66M | -11.81M | -8.32M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.17 | -1.18 | -1.10 | -2.17 | -2.22 |
| Normalized Basic EPS | -0.73 | -0.74 | -0.69 | -0.72 | -0.75 |
| EPS Diluted | -1.39 | -1.18 | -1.10 | -2.17 | -2.22 |
| Normalized Diluted EPS | -0.73 | -0.74 | -0.69 | -0.72 | -0.75 |
| Average Basic Shares Outstanding | 55.63M | 54.99M | 54.85M | 44.65M | 34.35M |
| Average Diluted Shares Outstanding | 55.63M | 54.99M | 54.85M | 44.65M | 34.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |